Entasis Therapeutics Holdings Inc

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Six abstracts selected for presentation, including three oral presentations Six abstracts selected for presentation, including three oral presentations

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022

Innoviva

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”) at a price of $2.20 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 5:00 p.m. New York City time on Thursday, July 7, 2022. The depositary for the tender offer has advised that, as of the exp

Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.

New York, New York--(Newsfile Corp. - June 21, 2022) - Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), relating to its proposed acquisition by Innoviva, Inc. Under the terms...

The M&A Class Action Firm Continues to Investigate Entasis Therapeutics Holdings Inc. - ETTX

WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the American Society for Microbiology (ASM) annual Microbe conference, taking place June 9-13, 2022, in Washington, DC. Entasis is presenting data on sulbactam-durlobactam (SUL-DUR), an investigational drug in development for the treatment of infections caused by Acinetobacter baumannii including carbapenem-resistant and multidrug-resistant (MDR) strains, and ETX0462 a novel, first-in-class, diazabicyclooctane with broad spectrum antimicrobial activity against MDR Gram-negative bacteria, including Pseudomonas aeruginosa.

Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the directors of Entasis Therapeutics Holdings Inc. (“Entasis”) (NASDAQ: ETTX) breached their fiduciary duties to its shareholders in approving a buyout with Innoviva, Inc. (“Innoviva”) (NASDAQ: INVA) for inadequate consideration. If you are an Entasis shareholder, you may contact attorney Joe Pettigrew for additional information

Scott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTX

NEW YORK , May 24, 2022 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) and its board of directors concerning the proposed acquisition of the company by Innoviva, Inc. (NASDAQ: INVA). Stockholders will receive $2.20 for each share of Entasis Therapeutics Holdings stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Entasis Therapeutics Holdings Inc.

Innoviva (INVA) is set to acquire Entasis (ETTX) for $2.20 per share in cash. The transaction is likely to close by third-quarter 2022.

Entasis (ETTX) Stock Rises on Buyout Offer From Innoviva

MILWAUKEE , May 24, 2022 /PRNewswire/ -- Ademi LLP is investigating Entasis (Nasdaq: ETTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Innoviva.  Click here to learn how to join the action: https://www.ademilaw.com/case/entasis-therapeutics-holdings-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Entasis Therapeutics Holdings Inc. has obtained a Fair Price in its transaction with Innoviva

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Entasis Therapeutics Holdings Inc. (NasdaqGM: ETTX) to Innoviva, Inc. (NasdaqGS: INVA). Under the terms of the proposed transaction, shareholders of Entasis will receive only $2.20 in cash for each share of Entasis that they own. KSF is seeking to determine whether this consideration and the process that led t

ENTASIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Entasis Therapeutics Holdings Inc. - ETTX

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) to Innoviva, Inc. for $2.20 per share in cash is fair to Entasis shareholders. Halper Sadeh encourages Entasis shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether E

ETTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Entasis Therapeutics Holdings Inc. Is Fair to Shareholders

Innoviva Inc (NASDAQ: INVA) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) at $2.20 per share in cash.  Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock.

Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share

BURLINGAME, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the companies have entered into a definitive merger agreement under w

Innoviva to Acquire Entasis Therapeutics

WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the company presented data highlights from its pivotal Phase 3 ATTACK trial at the American Thoracic Society (ATS) annual conference, held this week from May 16-18, 2022, in San Francisco, California.

Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference

WALTHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced its first quarter 2022 financial results and provided a business update.

Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update

Presentations Highlight Topline Results, Sub-Analysis for sulbactam-durlobactam (SUL-DUR) Presentations Highlight Topline Results, Sub-Analysis for sulbactam-durlobactam (SUL-DUR)

Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference

WALTHAM, Mass., April 18, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the company will deliver multiple data presentations on sulbactam-durlobactam (SUL-DUR) at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) annual conference, to be held April 23-26, 2022 in Lisbon, Portugal.

Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference

WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced full year 2021 financial results and provided a business update.

Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update

WALTHAM, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that its Board of Directors received a preliminary, non-binding proposal from its majority stockholder Innoviva, Inc. (“Innoviva”) to acquire all of the outstanding equity securities of Entasis that are not currently owned by Innoviva for a per share consideration of $1.80 payable in cash. The offer letter delivered by Innoviva to the Board of Directors is publicly available in the Schedule 13D amendment dated February 1, 2022 filed by Innoviva with the Securities and Exchange Commission.

Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.

WALTHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the Company will be participating in the H.C. Wainwright BioConnect 2022 investor conference, to be held virtually from January 10-13, 2022. Details for the event and management's participation are as follows:

Entasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022

Entasis Therapeutics Holdings Inc. (ETTX) CEO Manoussos Perros on Q3 2021 Results - Earnings Call Transcript

Management to host a conference call on November 4, 2021 at 8:00am ET Management to host a conference call on November 4, 2021 at 8:00am ET

Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report third quarter 2021 financial results before the market opens on November 4, 2021. The company will host a conference call and webcast at 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update. A question-and-answer session will follow management's prepared remarks.

Entasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021

Entasis' (ETTX) phase III ATTACK study achieves primary endpoint. The study evaluates its investigational combo drug SUL-DUR in infections caused by Acinetobacter baumannii.

Entasis' (ETTX) Phase III Study on Infection Drug Meets Goal

Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) announced topline results from its Phase 3 ATTACK trial of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with infections caused by Acinetobacter baumannii.  Colistin (polymyxin E) is an antibiotic medication used as a last resort for multidrug-resistant Gram-negative infections.

Entasis Shares Rally On Positive Data From Drug-Resistant Bacterial Infection Candidate

WALTHAM, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced topline results from its ATTACK trial―a global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results.   At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.

News for Entasis Therapeutics Holdings Inc Stock (ETTX)